Hepatocellular Carcinoma Drugs - Global Market Insights and Sales Trends 2024

• Description
• Table of Contents
• Table of Figures
• PDF Download

• Description
• Table of Contents
• Table of Figures
• PDF Download

HCC is the most common form of primary liver cancer in adults and occurs mainly in the patients with underlying liver disease and cirrhosis. The disease originates in the liver unlike the secondary liver cancers which reaches to the liver from other organs of the body. Currently only two drugs NEXAVAR and STIVARGA are approved for the treatment of the disease.

The global Hepatocellular Carcinoma Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Hepatocellular Carcinoma Drugs in various end use industries. The expanding demands from the Hospitals, Clinics and Cancer Rehabilitation Centers,, are propelling Hepatocellular Carcinoma Drugs market. Brachytherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Chemotherapy segment is estimated at % CAGR for the next seven-year period.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hepatocellular Carcinoma Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.

Key Features of The Study:
This report provides in-depth analysis of the global Hepatocellular Carcinoma Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.

This report profiles key players in the global Hepatocellular Carcinoma Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hepatocellular Carcinoma Drugs sales data, market share and ranking.

This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.

This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.

Key companies of Hepatocellular Carcinoma Drugs covered in this report include Bayer, Eli Lilly, Johnson and Johnson, Pfizer, Bristol-Myers Squibb, Celgene, F. Hoffmann-la Roche, Gilead and GlaxoSmithKline, etc.

The global Hepatocellular Carcinoma Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.

Market Segmentation

Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Hepatocellular Carcinoma Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion

 1 Market Overview of Hepatocellular Carcinoma Drugs
    1.1 Hepatocellular Carcinoma Drugs Market Overview
        1.1.1 Hepatocellular Carcinoma Drugs Product Scope
        1.1.2 Hepatocellular Carcinoma Drugs Market Status and Outlook
    1.2 Global Hepatocellular Carcinoma Drugs Market Size Overview by Region 2018 VS 2022 VS 2029
    1.3 Global Hepatocellular Carcinoma Drugs Market Size by Region (2018-2029)
    1.4 Global Hepatocellular Carcinoma Drugs Historic Market Size by Region (2018-2023)
    1.5 Global Hepatocellular Carcinoma Drugs Market Size Forecast by Region (2024-2029)
    1.6 Key Regions, Hepatocellular Carcinoma Drugs Market Size (2018-2029)
        1.6.1 North America Hepatocellular Carcinoma Drugs Market Size (2018-2029)
        1.6.2 Europe Hepatocellular Carcinoma Drugs Market Size (2018-2029)
        1.6.3 Asia-Pacific Hepatocellular Carcinoma Drugs Market Size (2018-2029)
        1.6.4 Latin America Hepatocellular Carcinoma Drugs Market Size (2018-2029)
        1.6.5 Middle East & Africa Hepatocellular Carcinoma Drugs Market Size (2018-2029)

 2 Hepatocellular Carcinoma Drugs Market by Type
    2.1 Introduction
        2.1.1 Brachytherapy
        2.1.2 Chemotherapy
        2.1.3 Local Ablation Therapy
    2.2 Global Hepatocellular Carcinoma Drugs Market Size by Type: 2018 VS 2022 VS 2029
        2.2.1 Global Hepatocellular Carcinoma Drugs Historic Market Size by Type (2018-2023)
        2.2.2 Global Hepatocellular Carcinoma Drugs Forecasted Market Size by Type (2024-2029)
    2.3 Key Regions Market Size by Type
        2.3.1 North America Hepatocellular Carcinoma Drugs Revenue Breakdown by Type (2018-2029)
        2.3.2 Europe Hepatocellular Carcinoma Drugs Revenue Breakdown by Type (2018-2029)
        2.3.3 Asia-Pacific Hepatocellular Carcinoma Drugs Revenue Breakdown by Type (2018-2029)
        2.3.4 Latin America Hepatocellular Carcinoma Drugs Revenue Breakdown by Type (2018-2029)
        2.3.5 Middle East and Africa Hepatocellular Carcinoma Drugs Revenue Breakdown by Type (2018-2029)

 3 Hepatocellular Carcinoma Drugs Market Overview by Application
    3.1 Introduction
        3.1.1 Hospitals
        3.1.2 Clinics
        3.1.3 Cancer Rehabilitation Centers
    3.2 Global Hepatocellular Carcinoma Drugs Market Size by Application: 2018 VS 2022 VS 2029
        3.2.1 Global Hepatocellular Carcinoma Drugs Historic Market Size by Application (2018-2023)
        3.2.2 Global Hepatocellular Carcinoma Drugs Forecasted Market Size by Application (2024-2029)
    3.3 Key Regions Market Size by Application
        3.3.1 North America Hepatocellular Carcinoma Drugs Revenue Breakdown by Application (2018-2029)
        3.3.2 Europe Hepatocellular Carcinoma Drugs Revenue Breakdown by Application (2018-2029)
        3.3.3 Asia-Pacific Hepatocellular Carcinoma Drugs Revenue Breakdown by Application (2018-2029)
        3.3.4 Latin America Hepatocellular Carcinoma Drugs Revenue Breakdown by Application (2018-2029)
        3.3.5 Middle East and Africa Hepatocellular Carcinoma Drugs Revenue Breakdown by Application (2018-2029)

 4 Hepatocellular Carcinoma Drugs Competition Analysis by Players
    4.1 Global Hepatocellular Carcinoma Drugs Market Size by Players (2018-2023)
    4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Hepatocellular Carcinoma Drugs as of 2022)
    4.3 Date of Key Players Enter into Hepatocellular Carcinoma Drugs Market
    4.4 Global Top Players Hepatocellular Carcinoma Drugs Headquarters and Area Served
    4.5 Key Players Hepatocellular Carcinoma Drugs Product Solution and Service
    4.6 Competitive Status
        4.6.1 Hepatocellular Carcinoma Drugs Market Concentration Rate
        4.6.2 Mergers & Acquisitions, Expansion Plans

 5 Company (Top Players) Profiles
    5.1 Bayer
        5.1.1 Bayer Profile
        5.1.2 Bayer Main Business
        5.1.3 Bayer Hepatocellular Carcinoma Drugs Products, Services and Solutions
        5.1.4 Bayer Hepatocellular Carcinoma Drugs Revenue (US$ Million) & (2018-2023)
        5.1.5 Bayer Recent Developments
    5.2 Eli Lilly
        5.2.1 Eli Lilly Profile
        5.2.2 Eli Lilly Main Business
        5.2.3 Eli Lilly Hepatocellular Carcinoma Drugs Products, Services and Solutions
        5.2.4 Eli Lilly Hepatocellular Carcinoma Drugs Revenue (US$ Million) & (2018-2023)
        5.2.5 Eli Lilly Recent Developments
    5.3 Johnson and Johnson
        5.3.1 Johnson and Johnson Profile
        5.3.2 Johnson and Johnson Main Business
        5.3.3 Johnson and Johnson Hepatocellular Carcinoma Drugs Products, Services and Solutions
        5.3.4 Johnson and Johnson Hepatocellular Carcinoma Drugs Revenue (US$ Million) & (2018-2023)
        5.3.5 Pfizer Recent Developments
    5.4 Pfizer
        5.4.1 Pfizer Profile
        5.4.2 Pfizer Main Business
        5.4.3 Pfizer Hepatocellular Carcinoma Drugs Products, Services and Solutions
        5.4.4 Pfizer Hepatocellular Carcinoma Drugs Revenue (US$ Million) & (2018-2023)
        5.4.5 Pfizer Recent Developments
    5.5 Bristol-Myers Squibb
        5.5.1 Bristol-Myers Squibb Profile
        5.5.2 Bristol-Myers Squibb Main Business
        5.5.3 Bristol-Myers Squibb Hepatocellular Carcinoma Drugs Products, Services and Solutions
        5.5.4 Bristol-Myers Squibb Hepatocellular Carcinoma Drugs Revenue (US$ Million) & (2018-2023)
        5.5.5 Bristol-Myers Squibb Recent Developments
    5.6 Celgene
        5.6.1 Celgene Profile
        5.6.2 Celgene Main Business
        5.6.3 Celgene Hepatocellular Carcinoma Drugs Products, Services and Solutions
        5.6.4 Celgene Hepatocellular Carcinoma Drugs Revenue (US$ Million) & (2018-2023)
        5.6.5 Celgene Recent Developments
    5.7 F. Hoffmann-la Roche
        5.7.1 F. Hoffmann-la Roche Profile
        5.7.2 F. Hoffmann-la Roche Main Business
        5.7.3 F. Hoffmann-la Roche Hepatocellular Carcinoma Drugs Products, Services and Solutions
        5.7.4 F. Hoffmann-la Roche Hepatocellular Carcinoma Drugs Revenue (US$ Million) & (2018-2023)
        5.7.5 F. Hoffmann-la Roche Recent Developments
    5.8 Gilead
        5.8.1 Gilead Profile
        5.8.2 Gilead Main Business
        5.8.3 Gilead Hepatocellular Carcinoma Drugs Products, Services and Solutions
        5.8.4 Gilead Hepatocellular Carcinoma Drugs Revenue (US$ Million) & (2018-2023)
        5.8.5 Gilead Recent Developments
    5.9 GlaxoSmithKline
        5.9.1 GlaxoSmithKline Profile
        5.9.2 GlaxoSmithKline Main Business
        5.9.3 GlaxoSmithKline Hepatocellular Carcinoma Drugs Products, Services and Solutions
        5.9.4 GlaxoSmithKline Hepatocellular Carcinoma Drugs Revenue (US$ Million) & (2018-2023)
        5.9.5 GlaxoSmithKline Recent Developments
    5.10 Merck
        5.10.1 Merck Profile
        5.10.2 Merck Main Business
        5.10.3 Merck Hepatocellular Carcinoma Drugs Products, Services and Solutions
        5.10.4 Merck Hepatocellular Carcinoma Drugs Revenue (US$ Million) & (2018-2023)
        5.10.5 Merck Recent Developments
    5.11 Novartis
        5.11.1 Novartis Profile
        5.11.2 Novartis Main Business
        5.11.3 Novartis Hepatocellular Carcinoma Drugs Products, Services and Solutions
        5.11.4 Novartis Hepatocellular Carcinoma Drugs Revenue (US$ Million) & (2018-2023)
        5.11.5 Novartis Recent Developments

 6 North America
    6.1 North America Hepatocellular Carcinoma Drugs Market Size by Country (2018-2029)
    6.2 U.S.
    6.3 Canada

 7 Europe
    7.1 Europe Hepatocellular Carcinoma Drugs Market Size by Country (2018-2029)
    7.2 Germany
    7.3 France
    7.4 U.K.
    7.5 Italy
    7.6 Russia
    7.7 Nordic Countries
    7.8 Rest of Europe

 8 Asia-Pacific
    8.1 Asia-Pacific Hepatocellular Carcinoma Drugs Market Size by Region (2018-2029)
    8.2 China
    8.3 Japan
    8.4 South Korea
    8.5 Southeast Asia
    8.6 India
    8.7 Australia
    8.8 Rest of Asia-Pacific

 9 Latin America
    9.1 Latin America Hepatocellular Carcinoma Drugs Market Size by Country (2018-2029)
    9.2 Mexico
    9.3 Brazil
    9.4 Rest of Latin America

 10 Middle East & Africa
    10.1 Middle East & Africa Hepatocellular Carcinoma Drugs Market Size by Country (2018-2029)
    10.2 Turkey
    10.3 Saudi Arabia
    10.4 UAE
    10.5 Rest of Middle East & Africa

 11 Hepatocellular Carcinoma Drugs Market Dynamics
    11.1 Hepatocellular Carcinoma Drugs Industry Trends
    11.2 Hepatocellular Carcinoma Drugs Market Drivers
    11.3 Hepatocellular Carcinoma Drugs Market Challenges
    11.4 Hepatocellular Carcinoma Drugs Market Restraints

 12 Research Finding /Conclusion

 13 Methodology and Data Source
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer

List of Tables
    Table 1. Global Market Hepatocellular Carcinoma Drugs Market Size (US$ Million) Comparison by Region 2018 VS 2022 VS 2029
    Table 2. Global Hepatocellular Carcinoma Drugs Market Size by Region (2018-2023) & (US$ Million)
    Table 3. Global Hepatocellular Carcinoma Drugs Market Size Share by Region (2018-2023)
    Table 4. Global Hepatocellular Carcinoma Drugs Forecasted Market Size by Region (2024-2029) & (US$ Million)
    Table 5. Global Hepatocellular Carcinoma Drugs Forecasted Market Size Share by Region (2024-2029)
    Table 6. Global Hepatocellular Carcinoma Drugs Market Size (US$ Million) by Type: 2018 VS 2022 VS 2029
    Table 7. Global Hepatocellular Carcinoma Drugs Market Size by Type (2018-2023) & (US$ Million)
    Table 8. Global Hepatocellular Carcinoma Drugs Revenue Market Share by Type (2018-2023)
    Table 9. Global Hepatocellular Carcinoma Drugs Forecasted Market Size by Type (2024-2029) & (US$ Million)
    Table 10. Global Hepatocellular Carcinoma Drugs Revenue Market Share by Type (2024-2029)
    Table 11. North America Hepatocellular Carcinoma Drugs Revenue by Type (2018-2023) & (US$ Million)
    Table 12. North America Hepatocellular Carcinoma Drugs Revenue by Type (2024-2029) & (US$ Million)
    Table 13. Europe Hepatocellular Carcinoma Drugs Revenue by Type (2018-2023) & (US$ Million)
    Table 14. Europe Hepatocellular Carcinoma Drugs Revenue by Type (2024-2029) & (US$ Million)
    Table 15. Asia-Pacific Hepatocellular Carcinoma Drugs Revenue by Type (2018-2023) & (US$ Million)
    Table 16. Asia-Pacific Hepatocellular Carcinoma Drugs Revenue by Type (2024-2029) & (US$ Million)
    Table 17. Latin America Hepatocellular Carcinoma Drugs Revenue by Type (2018-2023) & (US$ Million)
    Table 18. Latin America Hepatocellular Carcinoma Drugs Revenue by Type (2024-2029) & (US$ Million)
    Table 19. Middle East and Africa Hepatocellular Carcinoma Drugs Revenue by Type (2018-2023) & (US$ Million)
    Table 20. Middle East and Africa Hepatocellular Carcinoma Drugs Revenue by Type (2024-2029) & (US$ Million)
    Table 21. Global Hepatocellular Carcinoma Drugs Market Size (US$ Million) by Application: 2018 VS 2022 VS 2029
    Table 22. Global Hepatocellular Carcinoma Drugs Market Size by Application (2018-2023) & (US$ Million)
    Table 23. Global Hepatocellular Carcinoma Drugs Revenue Market Share by Application (2018-2023)
    Table 24. Global Hepatocellular Carcinoma Drugs Forecasted Market Size by Application (2024-2029) & (US$ Million)
    Table 25. Global Hepatocellular Carcinoma Drugs Revenue Market Share by Application (2024-2029)
    Table 26. North America Hepatocellular Carcinoma Drugs Revenue by Application (2018-2023) & (US$ Million)
    Table 27. North America Hepatocellular Carcinoma Drugs Revenue by Application (2024-2029) & (US$ Million)
    Table 28. Europe Hepatocellular Carcinoma Drugs Revenue by Application (2018-2023) & (US$ Million)
    Table 29. Europe Hepatocellular Carcinoma Drugs Revenue by Application (2024-2029) & (US$ Million)
    Table 30. Asia-Pacific Hepatocellular Carcinoma Drugs Revenue by Application (2018-2023) & (US$ Million)
    Table 31. Asia-Pacific Hepatocellular Carcinoma Drugs Revenue by Application (2024-2029) & (US$ Million)
    Table 32. Latin America Hepatocellular Carcinoma Drugs Revenue by Application (2018-2023) & (US$ Million)
    Table 33. Latin America Hepatocellular Carcinoma Drugs Revenue by Application (2024-2029) & (US$ Million)
    Table 34. Middle East and Africa Hepatocellular Carcinoma Drugs Revenue by Application (2018-2023) & (US$ Million)
    Table 35. Middle East and Africa Hepatocellular Carcinoma Drugs Revenue by Application (2024-2029) & (US$ Million)
    Table 36. Global Hepatocellular Carcinoma Drugs Revenue (US$ Million) by Players (2018-2023)
    Table 37. Global Hepatocellular Carcinoma Drugs Revenue Market Share by Players (2018-2023)
    Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Hepatocellular Carcinoma Drugs as of 2022)
    Table 39. Date of Key Players Enter into Hepatocellular Carcinoma Drugs Market
    Table 40. Global Hepatocellular Carcinoma Drugs Key Players Headquarters and Area Served
    Table 41. Hepatocellular Carcinoma Drugs Product Solution and Service
    Table 42. Global Hepatocellular Carcinoma Drugs Players Market Concentration Ratio (CR5 and HHI)
    Table 43. Mergers & Acquisitions, Expansion Plans
    Table 44. Bayer Basic Information List
    Table 45. Bayer Description and Business Overview
    Table 46. Bayer Hepatocellular Carcinoma Drugs Products, Services and Solutions
    Table 47. Revenue (US$ Million) in Hepatocellular Carcinoma Drugs Business of Bayer (2018-2023)
    Table 48. Bayer Recent Developments
    Table 49. Eli Lilly Basic Information List
    Table 50. Eli Lilly Description and Business Overview
    Table 51. Eli Lilly Hepatocellular Carcinoma Drugs Products, Services and Solutions
    Table 52. Revenue (US$ Million) in Hepatocellular Carcinoma Drugs Business of Eli Lilly (2018-2023)
    Table 53. Eli Lilly Recent Developments
    Table 54. Johnson and Johnson Basic Information List
    Table 55. Johnson and Johnson Description and Business Overview
    Table 56. Johnson and Johnson Hepatocellular Carcinoma Drugs Products, Services and Solutions
    Table 57. Revenue (US$ Million) in Hepatocellular Carcinoma Drugs Business of Johnson and Johnson (2018-2023)
    Table 58. Johnson and Johnson Recent Developments
    Table 59. Pfizer Basic Information List
    Table 60. Pfizer Description and Business Overview
    Table 61. Pfizer Hepatocellular Carcinoma Drugs Products, Services and Solutions
    Table 62. Revenue (US$ Million) in Hepatocellular Carcinoma Drugs Business of Pfizer (2018-2023)
    Table 63. Pfizer Recent Developments
    Table 64. Bristol-Myers Squibb Basic Information List
    Table 65. Bristol-Myers Squibb Description and Business Overview
    Table 66. Bristol-Myers Squibb Hepatocellular Carcinoma Drugs Products, Services and Solutions
    Table 67. Revenue (US$ Million) in Hepatocellular Carcinoma Drugs Business of Bristol-Myers Squibb (2018-2023)
    Table 68. Bristol-Myers Squibb Recent Developments
    Table 69. Celgene Basic Information List
    Table 70. Celgene Description and Business Overview
    Table 71. Celgene Hepatocellular Carcinoma Drugs Products, Services and Solutions
    Table 72. Revenue (US$ Million) in Hepatocellular Carcinoma Drugs Business of Celgene (2018-2023)
    Table 73. Celgene Recent Developments
    Table 74. F. Hoffmann-la Roche Basic Information List
    Table 75. F. Hoffmann-la Roche Description and Business Overview
    Table 76. F. Hoffmann-la Roche Hepatocellular Carcinoma Drugs Products, Services and Solutions
    Table 77. Revenue (US$ Million) in Hepatocellular Carcinoma Drugs Business of F. Hoffmann-la Roche (2018-2023)
    Table 78. F. Hoffmann-la Roche Recent Developments
    Table 79. Gilead Basic Information List
    Table 80. Gilead Description and Business Overview
    Table 81. Gilead Hepatocellular Carcinoma Drugs Products, Services and Solutions
    Table 82. Revenue (US$ Million) in Hepatocellular Carcinoma Drugs Business of Gilead (2018-2023)
    Table 83. Gilead Recent Developments
    Table 84. GlaxoSmithKline Basic Information List
    Table 85. GlaxoSmithKline Description and Business Overview
    Table 86. GlaxoSmithKline Hepatocellular Carcinoma Drugs Products, Services and Solutions
    Table 87. Revenue (US$ Million) in Hepatocellular Carcinoma Drugs Business of GlaxoSmithKline (2018-2023)
    Table 88. GlaxoSmithKline Recent Developments
    Table 89. Merck Basic Information List
    Table 90. Merck Description and Business Overview
    Table 91. Merck Hepatocellular Carcinoma Drugs Products, Services and Solutions
    Table 92. Revenue (US$ Million) in Hepatocellular Carcinoma Drugs Business of Merck (2018-2023)
    Table 93. Merck Recent Developments
    Table 94. Novartis Basic Information List
    Table 95. Novartis Description and Business Overview
    Table 96. Novartis Hepatocellular Carcinoma Drugs Products, Services and Solutions
    Table 97. Revenue (US$ Million) in Hepatocellular Carcinoma Drugs Business of Novartis (2018-2023)
    Table 98. Novartis Recent Developments
    Table 99. North America Hepatocellular Carcinoma Drugs Market Size by Country (2018-2023) & (US$ Million)
    Table 100. North America Hepatocellular Carcinoma Drugs Market Size by Country (2024-2029) & (US$ Million)
    Table 101. Europe Hepatocellular Carcinoma Drugs Market Size by Country (2018-2023) & (US$ Million)
    Table 102. Europe Hepatocellular Carcinoma Drugs Market Size by Country (2024-2029) & (US$ Million)
    Table 103. Asia-Pacific Hepatocellular Carcinoma Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 104. Asia-Pacific Hepatocellular Carcinoma Drugs Market Size by Region (2018-2023) & (US$ Million)
    Table 105. Asia-Pacific Hepatocellular Carcinoma Drugs Market Size by Region (2024-2029) & (US$ Million)
    Table 106. Asia-Pacific Hepatocellular Carcinoma Drugs Market Share by Region (2018-2023)
    Table 107. Asia-Pacific Hepatocellular Carcinoma Drugs Market Share by Region (2024-2029)
    Table 108. Latin America Hepatocellular Carcinoma Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 109. Latin America Hepatocellular Carcinoma Drugs Market Size by Country (2018-2023) & (US$ Million)
    Table 110. Latin America Hepatocellular Carcinoma Drugs Market Size by Country (2024-2029) & (US$ Million)
    Table 111. Middle East & Africa Hepatocellular Carcinoma Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 112. Middle East & Africa Hepatocellular Carcinoma Drugs Market Size by Country (2018-2023) & (US$ Million)
    Table 113. Middle East & Africa Hepatocellular Carcinoma Drugs Market Size by Country (2024-2029) & (US$ Million)
    Table 114. Hepatocellular Carcinoma Drugs Market Trends
    Table 115. Hepatocellular Carcinoma Drugs Market Drivers
    Table 116. Hepatocellular Carcinoma Drugs Market Challenges
    Table 117. Hepatocellular Carcinoma Drugs Market Restraints
    Table 118. Research Programs/Design for This Report
    Table 119. Key Data Information from Secondary Sources
    Table 120. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Hepatocellular Carcinoma Drugs Market Size Year-over-Year 2018-2029 & (US$ Million)
    Figure 2. Global Hepatocellular Carcinoma Drugs Market Size (US$ Million), 2018 VS 2022 VS 2029
    Figure 3. Global Hepatocellular Carcinoma Drugs Market Share by Regions: 2022 VS 2029
    Figure 4. Global Hepatocellular Carcinoma Drugs Forecasted Market Size Share by Region (2024-2029)
    Figure 5. North America Hepatocellular Carcinoma Drugs Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 6. Europe Hepatocellular Carcinoma Drugs Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 7. Asia-Pacific Hepatocellular Carcinoma Drugs Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 8. Latin America Hepatocellular Carcinoma Drugs Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 9. Middle East & Africa Hepatocellular Carcinoma Drugs Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 10. Product Picture of Brachytherapy
    Figure 11. Global Brachytherapy Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 12. Product Picture of Chemotherapy
    Figure 13. Global Chemotherapy Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 14. Product Picture of Local Ablation Therapy
    Figure 15. Global Local Ablation Therapy Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 16. Global Hepatocellular Carcinoma Drugs Market Size Share by Type:  2022 & 2029
    Figure 17. North America Hepatocellular Carcinoma Drugs Revenue Market Share by Type (2018-2029)
    Figure 18. Europe Hepatocellular Carcinoma Drugs Revenue Market Share by Type (2018-2029)
    Figure 19. Asia-Pacific Hepatocellular Carcinoma Drugs Revenue Market Share by Type (2018-2029)
    Figure 20. Latin America Hepatocellular Carcinoma Drugs Revenue Market Share by Type (2018-2029)
    Figure 21. Middle East and Africa Hepatocellular Carcinoma Drugs Revenue Market Share by Type (2018-2029)
    Figure 22. Hospitals Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 23. Clinics Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 24. Cancer Rehabilitation Centers Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 25. Global Hepatocellular Carcinoma Drugs Market Size Share by Application: 2022 & 2029
    Figure 26. North America Hepatocellular Carcinoma Drugs Revenue Market Share by Application (2018-2029)
    Figure 27. Europe Hepatocellular Carcinoma Drugs Revenue Market Share by Application (2018-2029)
    Figure 28. Asia-Pacific Hepatocellular Carcinoma Drugs Revenue Market Share by Application (2018-2029)
    Figure 29. Latin America Hepatocellular Carcinoma Drugs Revenue Market Share by Application (2018-2029)
    Figure 30. Middle East and Africa Hepatocellular Carcinoma Drugs Revenue Market Share by Application (2018-2029)
    Figure 31. Hepatocellular Carcinoma Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
    Figure 32. Global Top 5 and Top 10 Players Hepatocellular Carcinoma Drugs Market Share in 2022
    Figure 33. North America Hepatocellular Carcinoma Drugs Market Share by Country (2018-2029)
    Figure 34. U.S. Hepatocellular Carcinoma Drugs Market Size (2018-2029) & (US$ Million)
    Figure 35. Canada Hepatocellular Carcinoma Drugs Market Size (2018-2029) & (US$ Million)
    Figure 36. Germany Hepatocellular Carcinoma Drugs Market Size (2018-2029) & (US$ Million)
    Figure 37. France Hepatocellular Carcinoma Drugs Market Size (2018-2029) & (US$ Million)
    Figure 38. U.K. Hepatocellular Carcinoma Drugs Market Size (2018-2029) & (US$ Million)
    Figure 39. Italy Hepatocellular Carcinoma Drugs Market Size (2018-2029) & (US$ Million)
    Figure 40. Russia Hepatocellular Carcinoma Drugs Market Size (2018-2029) & (US$ Million)
    Figure 41. Nordic Countries Hepatocellular Carcinoma Drugs Market Size (2018-2029) & (US$ Million)
    Figure 42. Asia-Pacific Hepatocellular Carcinoma Drugs Market Share by Region (2018-2029)
    Figure 43. China Hepatocellular Carcinoma Drugs Market Size (2018-2029) & (US$ Million)
    Figure 44. Japan Hepatocellular Carcinoma Drugs Market Size (2018-2029) & (US$ Million)
    Figure 45. South Korea Hepatocellular Carcinoma Drugs Market Size (2018-2029) & (US$ Million)
    Figure 46. Southeast Asia Hepatocellular Carcinoma Drugs Market Size (2018-2029) & (US$ Million)
    Figure 47. India Hepatocellular Carcinoma Drugs Market Size (2018-2029) & (US$ Million)
    Figure 48. Australia Hepatocellular Carcinoma Drugs Market Size (2018-2029) & (US$ Million)
    Figure 49. Latin America Hepatocellular Carcinoma Drugs Market Share by Country (2018-2029)
    Figure 50. Mexico Hepatocellular Carcinoma Drugs Market Size (2018-2029) & (US$ Million)
    Figure 51. Brazil Hepatocellular Carcinoma Drugs Market Size (2018-2029) & (US$ Million)
    Figure 52. Middle East & Africa Hepatocellular Carcinoma Drugs Market Share by Country (2018-2029)
    Figure 53. Turkey Hepatocellular Carcinoma Drugs Market Size (2018-2029) & (US$ Million)
    Figure 54. Saudi Arabia Hepatocellular Carcinoma Drugs Market Size (2018-2029) & (US$ Million)
    Figure 55. UAE Hepatocellular Carcinoma Drugs Market Size (2018-2029) & (US$ Million)
    Figure 56. Bottom-up and Top-down Approaches for This Report

HCC is the most common form of primary liver cancer in adults and occurs mainly in the patients with underlying liver disease and cirrhosis. The disease originates in the liver unlike the secondary liver cancers which reaches to the liver from other organs of the body. Currently only two drugs NEXAVAR and STIVARGA are approved for the treatment of the disease.

The global Hepatocellular Carcinoma Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Hepatocellular Carcinoma Drugs in various end use industries. The expanding demands from the Hospitals, Clinics and Cancer Rehabilitation Centers,, are propelling Hepatocellular Carcinoma Drugs market. Brachytherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Chemotherapy segment is estimated at % CAGR for the next seven-year period.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hepatocellular Carcinoma Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.

Key Features of The Study:
This report provides in-depth analysis of the global Hepatocellular Carcinoma Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.

This report profiles key players in the global Hepatocellular Carcinoma Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hepatocellular Carcinoma Drugs sales data, market share and ranking.

This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.

This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.

Key companies of Hepatocellular Carcinoma Drugs covered in this report include Bayer, Eli Lilly, Johnson and Johnson, Pfizer, Bristol-Myers Squibb, Celgene, F. Hoffmann-la Roche, Gilead and GlaxoSmithKline, etc.

The global Hepatocellular Carcinoma Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.

Market Segmentation

Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Hepatocellular Carcinoma Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion